Groupe d'Etude en Oncologie du Quebec

Titre	A Phase 1/2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL-B01D1) Combinations in Adult Participants With Advanced Solid Tumors
Protocole ID	CA244-0001
ClinicalTrials.gov ID	NCT06618287
Type(s) de cancer	Tumeurs solides
Phase	Phase I-II
Type étude	Clinique
Médicament	BMS-986507 avec osimertinib et BMS-986507 avec pembrolizumab
Institution	CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS 3755 rue de la Côte Ste. Catherine, Montréal, QC, H3T 1E2
Ville	Montréal
Investigateur(trice) principal(e)	Dre Jennifer Friedmann
Coordonnateur(trice)	Karima Khebab 514-340-8222 poste 26187
Statut	Actif en recrutement
Critètes d'éligibilité	Participants must have at least one measurable lesion per response evaluation criteria in solid tumors. Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1. Participants must have a life expectancy of at least 3 months at the time of the first dose.
Critètes d'exclusion	Participants must not have any mixed Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC) histology. Participants must not have any untreated symptomatic central nervous system (CNS) metastases. Participants must not have a history of serious recurrent infections. Participants must not have a history of severe heart disease. Other protocol-defined Inclusion/Exclusion criteria apply.

Groupe d'étude en oncologie du Québec